Expression of TIP30 in HER-2-positive advanced breast cancer tissues and its clinical significance

LI Qi; LI Ai-min; LIU Xin-hui; CHEN Feng-sheng; CHEN Xu-jian; LUO Rong-cheng

doi:10.3969/j.issn.1002-266X.2014.21.003

Abstract：Objective To explore the expression of TIP 30 in epidermal growth factor receptor-2 ( HER-2 )-positive advanced breast cancer and its clinical significance. Me thods The expression of TIP30 was detected in 53 HER-2-positive advanced breast cancer tissues by immunohistochemistry .The tissues were obtained before biochemotherapy by Herceptin plus taxol ( TAX) .The relationship with clinicopathological parameters and biochemotherapy response was analyzed .Re-sults The positive expression rate of TIP30 was 56.6%in HER-2-positive advanced breast cancer tissues .There was no correlation between the expression of TIP30 protein and age, pathological pattern, metastasis, estrogen receptor (ER), and progestrone receptor ( PR) , but the expression of TIP 30 was associated with the functional status score and clinical efficacy (all P<0.05).After two cycles of biochemotherapy , the clinical benefit rate (CBR) was 54.7%.In 30 patients with positive TIP30 expression, the CBR was 73.3%(22/30), by contrast, the CBR was only 30.4%in 23 patients with neg-ative TIP30 expression, which showed a significant difference between the two groups (all P<0.05).The median progres-sion-free survival time was 11.47 and 4.87 months in patients with positive TIP30 expression and negative TIP30 expres-sion, respectively (all P<0.01).Conclusion The down-regulated TIP30 expression in HER-2-positive advanced breast cancer may be associated with the poor prognosis , which could be an important biomarker in predicting the efficacy of bio-chemotherapy in patients with HER-2-positive advanced breast cancer .